Display options
Cite
Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl). 1990;100(2):222-6doi: 10.1007/BF02244410.
Waldhauser, F., Saletu, B., & Trinchard-Lugan, I. (1990). Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology, 100(2), 222-6. https://doi.org/10.1007/BF02244410
Waldhauser, F, et al. "Sleep laboratory investigations on hypnotic properties of melatonin." Psychopharmacology vol. 100,2 (1990): 222-6. doi: https://doi.org/10.1007/BF02244410
Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl). 1990;100(2):222-6. doi: 10.1007/BF02244410. PMID: 2305009.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 1990;100(2):222-6. doi: 10.1007/BF02244410.

Sleep laboratory investigations on hypnotic properties of melatonin.

Psychopharmacology

F Waldhauser, B Saletu, I Trinchard-Lugan

Affiliations

  1. Department of Pediatrics, University of Vienna, Austria.

PMID: 2305009 DOI: 10.1007/BF02244410

Abstract

Melatonin (MLT), a pineal hormone, has some sedative and hypnotic properties. To explore this effect further 20 young, healthy volunteers exposed to artificial insomnia participated in a double-blind, placebo controlled, parallel group design study. They slept in a sleep laboratory for several consecutive nights and were polygraphically monitored and subjected to a battery of psychometric tests and standardized self-report questionnaires each morning. One night all subjects received only placebo (21:00 hours) and on a second night half of them were subjected to placebo and half to MLT. On the later night blood MLT levels were measured. Polygraphic recordings revealed that MLT at bedtime decreased the time the subjects were awake before sleep onset (P less than 0.025), sleep latency (P less than 0.05), and the number of awakenings during the total sleep period (P less than 0.025), and increased sleep efficiency (P less than 0.05). In addition, it decreased sleep stage 1 (P less than 0.05) and increased sleep stage 2 (P less than 0.025). On the morning following the treatment most objective and subjective measures for awakening quality showed a trend towards improvement after MLT. One hour after its oral administration, serum MLT rose to a high pharmacological level (25817 pg/ml; median), but individual peak serum MLT levels varied by a factor of 300.(ABSTRACT TRUNCATED AT 250 WORDS)

Similar articles

Panyatip P, Nunthaboot N, Puthongking P.
Int J Tryptophan Res. 2020 Dec 15;13:1178646920978245. doi: 10.1177/1178646920978245. eCollection 2020.
PMID: 33402831

Cited by

References

  1. Nature. 1967 May 27;214(5091):919-20 - PubMed
  2. Exp Brain Res. 1969;7(1):84-94 - PubMed
  3. Br J Clin Pharmacol. 1985 Apr;19(4):517-21 - PubMed
  4. Br J Pharmacol. 1982 May;76(1):95-101 - PubMed
  5. Neuropsychobiology. 1981;7(6):302-14 - PubMed
  6. Adv Biochem Psychopharmacol. 1974;11(0):187-91 - PubMed
  7. Int J Clin Pharmacol Res. 1987;7(5):407-18 - PubMed
  8. Clin Neuropharmacol. 1985;8 Suppl 1:S74-90 - PubMed
  9. Neurosci Lett. 1984 Apr 6;45(3):317-21 - PubMed
  10. Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10 - PubMed
  11. Experientia. 1964 Aug 15;20(8):435-7 - PubMed
  12. Dtsch Med Wochenschr. 1966 Dec 9;91(49):2214-6 - PubMed
  13. Adv Biochem Psychopharmacol. 1974;11(0):315-24 - PubMed
  14. Brain Res. 1984 Dec 10;323(2):201-7 - PubMed
  15. J Clin Psychopharmacol. 1983 Apr;3(2):133-9 - PubMed
  16. Life Sci I. 1971 Aug 1;10(15):841-50 - PubMed
  17. J Clin Endocrinol Metab. 1985 Dec;61(6):1214-6 - PubMed
  18. Neuroendocrinology. 1984 Oct;39(4):307-13 - PubMed
  19. Arzneimittelforschung. 1970 Jul;20(7):915-8 - PubMed
  20. Wien Med Wochenschr. 1984 Jan 31;134(2):29-35 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources